BioSpace News Archive

POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650).

Covalon Technologies Ltd. is pleased to announce that SurgiClear, the only dual antimicrobial postoperative dressing, is now part of the surgical site infection prevention bundle used by Texas Children’s Hospital Heart Unit after the dressing successfully eliminated surgical site infections.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its European commercial partner, STADA Arzneimittel AG, has launched the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive disease of the kidneys with a high unmet need.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing and measuring treatment response for various forms of hard to detect and treat cancer.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board.

SYNAPS Dx announces that Frank Amato, CEO and president, SDx will present at the HolonIQ New York Summit at 11 a.m. EST, September 22, 2022.

Lifespin GmbH, based in Regensburg, with offices in Boston, Massachusetts, announced that it has installed additional Nuclear Magnetic Resonance equipment which will double Lifespin’s annual laboratory testing capacity.

According to the global Nuclear Medicine market size was estimated at USD 9.50 billion in 2021 and is expected to surpass around USD 25.40 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.

According to Nova one advisor, the global In Vitro Fertilization /IVF market was valued at USD 638 million in 2021 and it is expected to hit around USD 2.4 billion by 2030 with a CAGR of 14.9% during the forecast period 2022 to 2030.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be participating in the Lytham Partners Fall 2022 Investor Conference, taking place virtually on September 28-29, 2022.